The FDA’s decision to expand approval of Sarepta’s (SRPT) Duchenne muscular dystrophy drug on Thursday could mean more “flexible” treatment from the agency for companies like Solid Biosciences (SLDB) and RegenxBio, which are each developing their own Duchenne gene therapies, STATNews’ Adam Feuerstein reports. According to Feuerstein, a biotech fund manager with a fairly large position in Sarepta believes that the FDA’s decision on Elevidsys is a net positive for the field of gene therapy and for patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi
- Sarepta rises as Pfizer âdisappointingâ DMD results remove competitor overhang
- Pfizer failure eliminates DMD competitor for Sarepta, says Baird
- Pfizer’s ‘disappointing’ Phase 3 results positive for Sarepta, says Mizuho
- Pfizer failure removes overhang for Sarepta, says Barclays